PATIENT‐REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY | Zendy

Prince H.M. | Zendy; Dummer R. | Zendy; Whittaker S. | Zendy; Horwitz S. | Zendy; Duvic M. | Zendy; Scarisbrick J. | Zendy; Quaglino P. | Zendy; Zinzani P.L. | Zendy; Wolter P. | Zendy; Sanches J. | Zendy; OrtizRomero P. | Zendy; Akilov O. | Zendy; Geskin L. | Zendy; Huen A. | Zendy; Wang Y. | Zendy; PalancaWessels M.C. | Zendy; Richhariya A. | Zendy; Feliciano J. | Zendy; Zhu Y. | Zendy; Lin H. | Zendy; Liu Y. | Zendy; Little M. | Zendy; Zagadailov E. | Zendy; Dalal M. | Zendy; Kim Y.H. | Zendy

Premium

PATIENT‐REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY

Author(s) -

Prince H.M.,

Dummer R.,

Whittaker S.,

Horwitz S.,

Duvic M.,

Scarisbrick J.,

Quaglino P.,

Zinzani P.L.,

Wolter P.,

Sanches J.,

OrtizRomero P.,

Akilov O.,

Geskin L.,

Huen A.,

Wang Y.,

PalancaWessels M.C.,

Richhariya A.,

Feliciano J.,

Zhu Y.,

Lin H.,

Liu Y.,

Little M.,

Zagadailov E.,

Dalal M.,

Kim Y.H.

Publication year - 2017

Publication title -

hematological oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.918

H-Index - 44

eISSN - 1099-1069

pISSN - 0278-0232

DOI - 10.1002/hon.2438_110

Subject(s) - brentuximab vedotin , mycosis fungoides , medicine , clinical endpoint , cutaneous t cell lymphoma , quality of life (healthcare) , population , bexarotene , cd30 , surrogate endpoint , lymphoma , oncology , randomized controlled trial , biochemistry , chemistry , nursing , environmental health , nuclear receptor , transcription factor , gene

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research